Incyte’s science-first approach and heritage in immunology has formed the foundation of our company. Today, we are building on this legacy as we discover and develop innovative inflammation and autoimmunity treatments to bring solutions to patients in need.
Our research and development efforts in inflammation and autoimmunity are anchored in our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition in chronic immune-mediated dermatologic conditions, including atopic dermatitis, vitiligo, hidradenitis suppurativa and prurigo nodularis.
Research has shown that the JAK-STAT pathway mediates the cellular effects of cytokines involved in the pathogenesis of many immune-mediated dermatologic conditions.
We strive to develop and deliver oral and topical solutions to modulate immune pathways driving uncontrolled inflammation to help restore normal immune function and bring the body closer to homeostasis.
Resources
FOR HEALTHCARE PROFESSIONALS
Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you need medical information or have a medical question, please visit incyteglobalmedicalinformation.com.
Please call Incyte European Medical Information department on 00 800 00027423 or Direct Dial for the UK only +44 1423 533 517 or email EU Incyte Call Center eumedinfo@incyte.com. For UK general enquiries, please email UK_enquiries@incyte.com.
UK Adverse Event Reporting Information:
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Incyte by calling 00 800 00027423.
Ireland Adverse Event Reporting Information:
Adverse events should be reported. Reporting forms and information can be found at: HPRA Pharmacovigilance Website: www.hpra.ie. Adverse events should also be reported to Incyte by calling 1800 456 748.